Efficacy and safety of low power holmium laser enucleation of the prostate: A prospective short- and medium-term single-blind randomized trial

被引:5
|
作者
Suh, Jungyo [1 ]
Choo, Min Soo [2 ,3 ]
Oh, Seung-June [3 ,4 ,5 ]
机构
[1] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Urol, Seoul, South Korea
[2] SMG SNU Boramae Med Ctr, Dept Urol, Seoul, South Korea
[3] Seoul Natl Univ, Coll Med, Dept Urol, Seoul, South Korea
[4] Seoul Natl Univ Hosp, Dept Urol, Seoul, South Korea
[5] Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Dept Urol, 101 Daehak Ro, Seoul 03080, South Korea
关键词
Benign prostatic hyperplasia; Clinical trial; Holmium laser; Transurethral prostatectomy; HOLEP;
D O I
10.4111/icu.20230017
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We evaluated the efficacy and safety of mid-term follow-up in low-power (LP) Holmium laser enucleation of the prostate (HoLEP) compared with high-power (HP) surgery for benign prostatic hyperplasia (BPH).Materials and Methods: This prospective, single-blind, randomized controlled study was conducted between September 2020 and April 2021. Ninety male patients >50 years who underwent HoLEP for BPH were randomly assigned to HP (80 W/2 J/40 Hz) and LP (24 W/2 J/12 Hz) groups. The primary endpoint was the total International Prostate Symptom Score (IPSS) six months after surgery. The secondary endpoints were perioperative results and postoperative outcomes at two weeks, three and six months after the surgery, including Clavien-Dindo complication classification.Results: At six months after HoLEP, 41 and 42 patients were followed up in the HP and LP groups, respectively. There was no difference in the preoperative characteristics between the two groups. The prostate volumes were 67.1 +/- 23.7 mL for the HP group and 64.3 +/- 25.7 mL for the LP group (p=0.592), respectively. Although the total operative time was significantly longer by 13.1 minutes in the LP group (47.8 +/- 20.3 min vs. 60.9 +/- 23.3 min, p=0.006), the total delivered energy was significantly lower, which was only about 68% of the HP group (58.2 +/- 23.9 kJ vs. 39.9 +/- 13.2 kJ, p<0.001). Surgical outcomes significantly improved postoperatively in both groups compared to baseline, except for storage symptoms. Improvement in IPSS storage subscore was observed from the immediate postoperative 2 weeks in the LP group (8.1 +/- 3.1 to 6.9 +/- 3.8, p<0.001), whereas there was no significant recovery in the HP group (8.0 +/- 3.2 to 7.7 +/- 3.4, p=0.842). In the 6-month follow, there was no significant difference between the two groups in the IPSS total score (5.9 +/- 5.6 vs. 7.3 +/- 5.3, p=0.260) as well as IPSS storage subscore. In addition, there was no significant difference in postoperative complications, including bleeding or urinary incontinence, between the two groups.Conclusions: The HoLEP procedure performed using an LP laser device resulted in lower total delivered energy, faster recovery, and significantly improved surgical outcomes up to mid-term follow-up. There was no difference in efficiency or safety between the HP device system.
引用
收藏
页码:480 / 488
页数:9
相关论文
共 50 条
  • [31] PROSPECTIVE RANDOMIZED TRIAL ASSESSING THE SEVERITY OF IRRITATIVE SYMPTOMS AFTER HOLMIUM LASER ENUCLEATION OF THE PROSTATE (HOLEP) VERSUS THULIUM FIBER LASER ENUCLEATION OF THE PROSTATE (THUFLEP)
    Enikeev, Dmitry
    Taratkin, Mark
    Babaevskaya, Diana
    Petov, Vladislav
    Enikeev, Mikhail
    Sukhanov, Roman
    Shpot, Evgeny
    Chinenov, Denis
    Herrmann, Thomas
    JOURNAL OF UROLOGY, 2022, 207 (05): : E476 - E477
  • [32] Prospective randomized trial assessing the severity of irritative symptoms after Holmium Laser Enucleation of the Prostate (HoLEP) versus Thulium Fiber Laser Enucleation of the Prostate (ThuFLEP)
    Enikeev, D.
    Taratkin, M.
    Babaevskaya, D.
    Petov, V
    Enikeev, M.
    Sukhanov, R.
    Shpot, E.
    Chinenov, D.
    Herrmann, T.
    EUROPEAN UROLOGY, 2022, 81 : S1295 - S1295
  • [33] Perioperative Safety and Efficacy of Holmium Laser Enucleation of the Prostate in Patients Receiving Antithrombotic Therapy: A Prospective Cohort Study
    Hyeong Dong Yuk
    Seung-June Oh
    Scientific Reports, 10
  • [34] Does Resectoscope Sheath Size Influence Holmium Laser Enucleation of the Prostate Outcomes? A Prospective Randomized Controlled Trial
    Dean, Nicholas S.
    Lee, Matthew S.
    Assmus, Mark A.
    Guo, Jenny
    Xu, Perry
    Mcdonald, Alyssa
    Fadl-Alla, Alla
    Helin, Jessica
    Krambeck, Amy E.
    JOURNAL OF ENDOUROLOGY, 2023, 37 (12) : 1261 - 1269
  • [35] Perioperative Safety and Efficacy of Holmium Laser Enucleation of the Prostate in Patients Receiving Antithrombotic Therapy: A Prospective Cohort Study
    Yuk, Hyeong Dong
    Oh, Seung-June
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [36] MOSES™ TECHNOLOGY FOR HOLMIUM ENUCLEATION OF THE PROSTATE: EXTENDED OUTCOMES FROM A PROSPECTIVE DOUBLE-BLIND RANDOMIZED CONTROL TRIAL
    Setia, Shaan
    Kavoussi, Nicholas
    Miller, Nicole
    JOURNAL OF UROLOGY, 2022, 207 (05): : E61 - E62
  • [37] Moses 2.0 Technology for holmium laser enucleation of the prostate in the treatment of BPH: Prospective randomized double-blind study
    Sun, J.
    Xia, S.
    Tricard, T.
    Tong, Z.
    Chen, B.
    EUROPEAN UROLOGY, 2024, 85 : S915 - S915
  • [38] Efficacy and Safety of Tranexamic Acid in Intertrochanteric Fractures: A Single-Blind Randomized Controlled Trial
    Zhou, Xin-die
    Zhang, Yi
    Jiang, Li-feng
    Zhang, Jun-jie
    Zhou, Dong
    Wu, Li-dong
    Huang, Yong
    Xu, Nan-wei
    ORTHOPAEDIC SURGERY, 2019, 11 (04) : 635 - 642
  • [39] Safety and efficacy using a low-powered holmium laser for enucleation of the prostate (HoLEP): 12-month results from a prospective low-power HoLEP series
    B. Becker
    A. J. Gross
    C. Netsch
    World Journal of Urology, 2018, 36 : 441 - 447
  • [40] Safety and efficacy using a low-powered holmium laser for enucleation of the prostate (HoLEP): 12-month results from a prospective low-power HoLEP series
    Becker, B.
    Gross, A. J.
    Netsch, C.
    WORLD JOURNAL OF UROLOGY, 2018, 36 (03) : 441 - 447